Prescribing Habits for Androgenetic Alopecia among Dermatologists in Spain in 2024: A Cross-Sectional Study

The management of androgenetic alopecia (AGA) is evolving. This study updates current prescribing practices compared with 2019–2020. A digital survey was conducted among dermatologists in Spain between March and June 2024, focusing on AGA treatment trends, nutricosmetic product selection, and the adoption of hair skinification.A total of 202 dermatologists participated, including 164 attending physicians and 38 residents. AGA remained the most frequent cause of alopecia consultation (51%). Oral minoxidil was the most prescribed treatment for male AGA (89.1%), premenopausal female AGA (92.1%), and postmenopausal female AGA (93.1%).There has been a shift toward oral minoxidil and a decline in topical formulations. Oral dutasteride has now replaced finasteride as the most widely prescribed antiandrogen for male AGA, reflecting its growing acceptance despite off-label use. For premenopausal AGA, spironolactone is now the most frequently chosen antiandrogen, surpassing oral contraceptives and finasteride. Meanwhile, dutasteride has become the predominant antiandrogen for postmenopausal AGA, replacing finasteride.